BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen

Executive Summary

• BetterLife Pharma highlighted the non‑hallucinogenic profile of its lead candidate BETR‑001 and its advantage over traditional LSD microdosing.
• The company announced completion of remaining IND‑enabling studies with plans to file an IND and commence human clinical trials in the second half of 2026, initially targeting traumatic brain injury, cluster headaches, and migraine.
• A secondary drug candidate for viral infections is being explored for strategic alternatives.

Key Details

• BETR‑001 is a proprietary non‑hallucinogenic LSD derivative that remains free of hallucinations even at full therapeutic doses, enabling chronic dosing without tolerance.
• Preclinical data suggest neuroplastogenic effects require sufficient dosing; BETR‑001 can be administered at full dose to achieve this effect.
• CEO Dr. Ahmad Doroudian emphasized the clinical advantage of avoiding in‑clinic monitoring (8–12 hours) required for traditional psychedelic therapies.
• IND‑enabling studies are now complete; filing of the Investigational New Drug application is planned for 2H 2026, after which human trials will begin.
• Initial therapeutic focus: traumatic brain injury (TBI), cluster headaches, and migraine; broader psychiatric indications to be evaluated as development progresses.
• The company holds a synthesis patent that eliminates regulatory hurdles and a pending composition/method‑of‑use patent covering neurological disorders through approximately 2042.
• BetterLife also possesses a separate drug candidate targeting viral infections and is seeking strategic alternatives for its further development.

Notable Quotes

“The importance of being able to give full doses of BETR‑001 without hallucinations cannot be over‑emphasized… BETR‑001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations.” – Dr. Ahmad Doroudian, CEO

“We are completing the last remaining BETR‑001 IND‑enabling studies and plan to file the IND and begin human clinical trials by 2H 2026… our initial scope is to develop BETR‑001 for treatment of traumatic brain injury, cluster headaches and migraine.” – Dr. Ahmad Doroudian, CEO